Chapter 8: The White Cells, Part 1: Granulocytes, Monocytes and Their Benign Disorders

The White Cells, Part 1: Granulocytes, Monocytes and Their Benign Disorders phagocytic cells are categorized into neutrophils, eosinophils, and basophils based on their distinct staining properties and functional roles. Neutrophil development, or granulopoiesis, occurs in the bone marrow through a regulated progression from myeloblasts to mature segmented cells, a process heavily influenced by colony-stimulating factors like G-CSF. Mature neutrophils are primarily responsible for identifying and neutralizing bacterial threats through a sequence of chemotaxis, opsonization, and intracellular killing via oxidative bursts and antimicrobial proteins. The text details various quantitative and qualitative abnormalities, such as reactive neutrophilia seen in infections and inflammation, and the leukaemoid or leucoerythroblastic reactions where immature precursors enter the peripheral blood. Conversely, neutropenia—a dangerous reduction in cell counts—can arise from genetic mutations, drug toxicities, or autoimmune destruction, necessitating clinical intervention with recombinant growth factors. Eosinophils and basophils are highlighted for their specific roles in mediating allergic responses and defending against parasitic infestations. Furthermore, the chapter delves into monocyte-derived cells, including tissue macrophages and dendritic cells, which bridge the gap between innate and adaptive immunity through antigen presentation. Clinical syndromes involving these lineages range from benign morphological anomalies like the Pelger-Huët or May-Hegglin traits to life-threatening conditions such as haemophagocytic lymphohistiocytosis (HLH) and Langerhans’ cell histiocytosis. Finally, the discussion covers hereditary lysosomal storage diseases, specifically focusing on Gaucher disease, where enzyme deficiencies lead to glycolipid accumulation within the reticuloendothelial system, causing splenomegaly, skeletal damage, and cytopenias that are now manageable through sophisticated enzyme replacement and substrate reduction therapies.